- Also known as
- SLU PP 332 · SLU-PP 332 · SLUPP332 · pan-ERR agonist SLU-PP-332
- Class
- Synthetic pan-ERR (ERRα/β/γ) agonist, small molecule
- Form
- Lyophilised powder in 5 mg vials and capsules
- Sizes
- 5 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C once in solution; stability in solution is not reported in these records
- BAC water per size
- 5 mg: 2 mL
- Molecular weight
- 290.3 g/mol (C18H14N2O2)
What is SLU-PP-332?
The literature describes SLU-PP-332 as synthetic pan-ERR (ERRα/β/γ) agonist, small molecule. Its molecular weight is 290.3 g/mol (C18H14N2O2). The name covers the same material written several ways in the literature, including SLU PP 332, SLU-PP 332 and SLUPP332. Its sequence is recorded as Not a peptide: a small-molecule hydrazone, (E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide. Published work on it is in mouse, in vitro and cell culture. No human study of SLU-PP-332 has been published, so nothing on this page describes what it does in a person. Borealis Peptides supplies it as lyophilised powder in 5 mg vials and capsules for in-vitro laboratory research. Nothing here is a medicine; it is not for human or veterinary use.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Billon C et al.2024 · J Pharmacol Exp Ther · PMID 37739806 | Mouse, diet-induced obese and ob/ob models of obesity and metabolic syndrome | Not stated in the abstract | Not stated in the abstract | SLU-PP-332 increased energy expenditure and fatty acid oxidation and decreased fat mass accumulation. It reduced obesity and improved insulin sensitivity in the metabolic syndrome models. |
| Xu W et al.2024 · Circulation · PMID 37961903 | Mouse, pressure overload-induced heart failure; cardiomyocyte cell work in vitro | Not stated in the abstract | 6-week pressure overload (treatment length not stated in the abstract) | SLU-PP-332 and SLU-PP-915 improved ejection fraction, reduced fibrosis and increased survival without affecting cardiac hypertrophy. They activated fatty acid and mitochondrial genes, and genetic dependency experiments showed ERRγ as the main mediator. |
| Okda HE et al.2026 · Int J Biol Macromol · PMID 41850449 | Cell culture, cell-based functional assays with computational modelling (structure-activity study) | Not stated in the abstract | Not stated in the abstract | The first full structure-activity analysis of the SLU-PP-332 scaffold identified the structural features that control ERRα and ERRγ agonism. Several analogues matched it with better ligand efficiency, solubility or metabolic stability, and SLU-PP-332 remained a benchmark for ERR activation. |
| Avliyakulov NK et al.2026 · Drug Test Anal · PMID 41688415 | In vitro, pooled human liver S9 fractions (metabolite identification) | Not stated in the abstract | Not stated in the abstract | 22 Phase I and II metabolites were identified by LC-MS/HRMS, including hydroxylated, glucuronidated and sulfated forms. Eight of them were the most abundant and potentially useful for doping control. |
| Möller T et al.2026 · Rapid Commun Mass Spectrom · PMID 41588687 | In vitro, human liver S9 fraction and human liver microsomes (analytical characterisation) | Not stated in the abstract | Not stated in the abstract | Nine metabolites were identified for SLU-PP-332: six Phase I metabolites and three Phase II conjugates. The authors describe the data as a basis for detecting its misuse as a performance-enhancing substance. |
What these studies don't show: No part of this evidence came from a person. Nothing here supports a claim about human effects, and none is made. An effect in culture or in a mouse is a starting point for research, not a conclusion about people. Knowing the vial holds what the label says is not the same as knowing the compound does anything.
Every study links to its PubMed record. See all SLU-PP-332 studies in the research library →
SLU-PP-332 price in Canada: 5mg vial
Buy SLU-PP-332 in Canada in a 5mg vial, plus capsules and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 5 mg | $71.00 | $14.20/mg |
Other formats and kits
Is SLU-PP-332 available in Canada?
SLU-PP-332 has no Drug Identification Number, which is how Health Canada marks a drug it has authorized. No regulatory assessment of its safety, efficacy or quality has been carried out in Canada. It is stocked here as laboratory research material and for no use in a person or an animal. How Health Canada treats research peptides →
Side effects reported in studies
Absence of a reported effect in a small study is not evidence of safety. Each statement is tied to the study that reported it. None of the cited abstracts states a tolerability finding for SLU-PP-332. Read more →
Doses used in studies
SLU-PP-332 FAQ
What is SLU-PP-332?
SLU-PP-332 is a synthetic pan-ERR (ERRα/β/γ) agonist, small molecule, and that classification is where the published work starts. The published work on it is in mouse, in vitro and cell culture. Borealis Peptides supplies it as lyophilised powder in 5 mg vials and capsules for in-vitro laboratory research. It is not a medicine and is not for use in humans or animals. The table on this page gives each study, its model and its reported result.
Where can I buy SLU-PP-332 in Canada?
Borealis Peptides ships SLU-PP-332 from Canadian stock to research and business addresses in Canada. It is held in 5 mg vials. Every batch is tested by HPLC and the certificate names the batch in your vial. Orders are accepted for laboratory research only.
Is SLU-PP-332 legal in Canada?
SLU-PP-332 has no Drug Identification Number, which is how Health Canada marks a drug it has authorized. No regulatory assessment of its safety, efficacy or quality has been carried out in Canada. It is stocked here as laboratory research material and for no use in a person or an animal. Health Canada has said that "Research Use Only" labelling does not make a product legal to use in a person, so we treat it as a description of what the material is supplied for rather than a permission.
How much SLU-PP-332 should I use?
We do not answer dosing questions. SLU-PP-332 is not supplied for use in a person or an animal, so there is no dose to describe. What this page carries is the amount each cited study used and the model it used it in, reproduced as the authors published it.
Has SLU-PP-332 been tested in people?
No. The 5 studies cited here used animals or cell culture. There is no published human study of SLU-PP-332, so there is no evidence about what it does in a person, and this page makes no claim about that. The animal work is listed with its model so it can be read for what it is.
What storage does SLU-PP-332 need?
Sealed vials are held at −20 °C, dry and out of the light. In solution it is kept at 2–8 °C once in solution; stability in solution is not reported in these records. Ambient transit does not harm the dry powder, which should be refrigerated once received. Light and repeated warming do more damage than the journey.
Does SLU-PP-332 need bacteriostatic water?
The capsules are a dry oral format and take no liquid. Only the lyophilised vial is supplied dry, and that is the one format bacteriostatic water applies to. It is sold separately. HPLC runs on each batch, and the certificate you receive refers to the batch you were sent.
How is the purity of SLU-PP-332 confirmed?
Identity and purity are confirmed by HPLC for each batch, not once per product. The certificate names the batch it belongs to, and that batch number is on the vial, so a result can be traced back to the exact material that produced it. Ask with your order number and we send it.
How does SLU-PP-332 compare with MOTS-C and 5-Amino-1MQ?
These are separate compounds with separate literatures; no ranking is offered here. MOTS-C and 5-Amino-1MQ have 7 cited studies and 7 cited studies on their page against 5 here. Set the two evidence tables side by side and the difference is visible directly.
Compare with
Related compounds
5-Amino-1MQ
Small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor
Add 2 more to save 4%
SS-31
Mitochondria-targeting tetrapeptide (cardiolipin binder)
Add 2 more to save 4%
